Scribe Therapeutics Inc. SCTX
16.78 USD +0.58 (+3.58%)
At closeNov 4, 2026, 4:10 PM EST
17.00 +0.22 +1.31%
After hours · Nov 4, 4:10 PM ET
16.25 Day range 17.48
13.50 52-week range 39.60
- YTD
- -11.54%
- 1 year
- -11.54%
- Market cap
- 317.67M
- EPS (ttm)
- -3.97
- YTD return
- -11.54%
- 1-year return
- -11.54%
- Volume
- 263.06K
- Avg volume
- 378.85K
- Open
- 16.58
- Previous close
- 16.20
- Day's range
- 16.25 – 17.48
- 52-week range
- 13.50 – 39.60
2Y -2.22 (-11.70%)
Financials — quick view
SCTX Revenue — quarterly 1.92M
SCTX Net income — quarterly -6.48M
SCTX EPS — quarterly -2.62
News
Scribe Therapeutics To Present Data In American Heart Association’s Scientific Sessions On Its Three Clinical Programs 
Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026 
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought 
Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst 
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday 
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Scribe Therapeutics Inc. (NASDAQ:SCTX) Stock Rated “Moderate Buy” by Wall Street Analysts 
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on SCTX — it syncs with the Stock Master app.